FL-AERA-TECHNOLOGY
Gartner Supply Chain Symposium/Xpo™ 2022 — Aera Technology today announced from the Gartner® Supply Chain Symposium/Xpo™ 2022, the release of new AI/MLOps and developer capabilities for its Aera Decision Cloud™ platform. To speed and scale decision automation, these enhancements add to the platform’s data science engine and provide advanced features for understanding the relationships and effectiveness of decisions. The innovations also strengthen Aera Decision Cloud’s capabilities for supply chain decision flows.
Aera Decision Cloud is designed to accelerate the adoption of Decision Intelligence — the digitization, augmentation, and automation of decision making. It enables companies to make and execute decisions in real-time to optimize business, financial, and operational performance.
According to Gartner, “by 2025, 95% of decisions that currently use data will be at least partially automated.”* Implementing and scaling automated decision-making across one or multiple business functions is difficult and time-consuming without a purpose-built platform. Aera Decision Cloud was designed from the start to empower users with the advanced technologies and tools, in one platform, to aggregate and integrate data from internal and external systems and sources and build and deploy decision-making models that generate informed, automated recommendations for any business scenario.
Today’s product release provides new features for business users that advance and scale Aera Cognitive Skills™ — the platform’s pre-built set of comprehensive decision-making capabilities for demand forecasting, planning, inventory, logistics, procurement, finance, revenue, and more. The release also delivers enhancements for data engineers, data scientists, and developers that optimize their experience in Aera Developer™ , the platform’s integrated development environment (IDE) for creating and deploying Skills, or modifying any deployed Aera Cognitive Skills.
Product release highlights:
-
Enhancements to Aera Cortex™
, the data science engine inside the Aera Cognitive Operating System™
, to improve the user experience, including:
- New Aera Notebook : Jupyter Notebook open interface provides the ideal environment to easily integrate data science projects and other custom code using Python and R, into Decision Intelligence flows, right from the Aera Decision Cloud platform.
- New AutoML : Machine learning options enable development of ML decision models — without requiring expertise in model creation, tuning, and deployment.
- New Model Performance and Versioning : New enhancements automate monitoring, deployment, and versioning of machine learning models to make it much easier to operationalize ML models and scale across the entire enterprise.
-
Advanced intelligence capabilities to provide a deeper understanding of relationships and effectiveness of decisions, including:
- New Graph Explorer : Advanced graph capabilities to enable data relationships to be used effectively in the decision-making process.
- New Confidence Score : Confidence score framework, which learns from past, similar recommendations and outcomes, helps determine the decisions that can be automated.
- New Action Item Node : Addition of a node within the Aera Developer environment to simplify decision management through the ability to more easily create, update, close, and access recommendations.
“Through Aera Decision Cloud, we are re-inventing decision making and accelerating adoption of Decision Intelligence,” said Shariq Mansoor, Founder and Chief Technology Officer, Aera Technology. "Today’s comprehensive release for both business end user and data science teams underscores how we are continually advancing and evolving our platform to enable digital decisions at scale in this increasingly complex business environment.”
To see a demo of Aera Decision Cloud and the new features, visit the Aera team at Booth #325, Gartner Supply Chain Symposium/Xpo™ 2022 .
About the Gartner Supply Chain Symposium/Xpo™
Gartner Supply Chain Symposium/Xpo delivers the must-have insights, strategies and frameworks for CSCOs and supply chain leaders to drive impact within their organizations. Supply chain leaders will gather to gain a strategic view of the trends disrupting their business and the insights and frameworks they can use to prepare for disruption, enable digital transformation and build sustainability as a competitive advantage.
*Gartner, “ Predicts 2022: Data and Analytics Strategies Build Trust and Accelerate Decision Making,” Jorgen Heizenberg, Lydia Clougherty Jones, Ted Friedman, Andrew White, Saul Judah, Gareth Herschel, Rita Sallam, Ehtisham Zaidi, Svetlana Sicular, December 2021. https://www.gartner.com/document/4008991
GARTNER and SUPPLY CHAIN SYMPOSIUM/XPO ™ are registered trademarks and service marks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.
About Aera Technology
Aera Technology is the Decision Intelligence company that makes business agility happen. The company’s innovative cloud platform integrates with existing systems to make and execute business decisions in real time. In the era of digital acceleration, Aera helps enterprises around the world transform how they respond to the ever-changing environment. For more information, visit www.aeratechnology.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005098/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom